These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1925165)

  • 41. Successful program for recovery of dropouts to a clinical trial.
    Probstfield JL; Russell ML; Henske JC; Reardon RJ; Insull W
    Am J Med; 1986 May; 80(5):777-84. PubMed ID: 3706364
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Coronary prevention study yields proof of cholesterol link.
    Schrott HG
    Iowa Med; 1984 Apr; 74(4):143-6. PubMed ID: 6376416
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
    Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
    J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [CARE[ Cholesterol and Recurrent Events Trial]].
    Oida K
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():427-32. PubMed ID: 11347108
    [No Abstract]   [Full Text] [Related]  

  • 45. [Interim analysis in clinical trials: a methodological guide].
    Muñoz Navarro SR; Bangdiwala SI
    Rev Med Chil; 2000 Aug; 128(8):935-41. PubMed ID: 11129556
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [J-LIT [Japan Lipid Intervention Trial]].
    Itakura H
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():462-8. PubMed ID: 11347114
    [No Abstract]   [Full Text] [Related]  

  • 47. Central and statistical data monitoring in the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2) trial.
    Edwards P; Shakur H; Barnetson L; Prieto D; Evans S; Roberts I
    Clin Trials; 2014 Jun; 11(3):336-343. PubMed ID: 24346610
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Bayesian approach for inference from a bridging study with binary outcomes.
    Gandhi M; Mukherjee B; Biswas D
    J Biopharm Stat; 2012 Sep; 22(5):935-51. PubMed ID: 22946941
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study.
    Am J Cardiol; 1995 Sep; 76(7):485-91. PubMed ID: 7653449
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Test homogeneity of odds ratio in a randomized clinical trial with noncompliance.
    Lui KJ; Chang KC
    J Biopharm Stat; 2009 Sep; 19(5):916-32. PubMed ID: 20183452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
    Collins R; Armitage J; Parish S; Sleight P; Peto R;
    Lancet; 2004 Mar; 363(9411):757-67. PubMed ID: 15016485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Planning the type II coronary primary prevention trial of the lipid research clinics (U. S. A.).
    Steinberg D
    Adv Exp Med Biol; 1975; 63():417-26. PubMed ID: 1106141
    [No Abstract]   [Full Text] [Related]  

  • 53. Bayesian predictive approach to interim monitoring in clinical trials.
    Dmitrienko A; Wang MD
    Stat Med; 2006 Jul; 25(13):2178-95. PubMed ID: 16007570
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selections from current literature: the fight over fat: is pharmacological lipid lowering useful for coronary primary prevention?
    Green L
    Fam Pract; 1997 Oct; 14(5):411-5. PubMed ID: 9472378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Report on the Lipid Research Clinic trials.
    Levy RI
    Eur Heart J; 1987 Aug; 8 Suppl E():45-53. PubMed ID: 3315677
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.
    Sacks FM; Tonkin AM; Shepherd J; Braunwald E; Cobbe S; Hawkins CM; Keech A; Packard C; Simes J; Byington R; Furberg CD
    Circulation; 2000 Oct; 102(16):1893-900. PubMed ID: 11034935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
    Albert MA; Staggers J; Chew P; Ridker PM;
    Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reducing overestimation of the treatment effect by interim analysis when designing clinical trials.
    Shimura M
    J Clin Pharm Ther; 2019 Apr; 44(2):243-248. PubMed ID: 30414384
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.
    Schrott HG; Bittner V; Vittinghoff E; Herrington DM; Hulley S
    JAMA; 1997 Apr 23-30; 277(16):1281-6. PubMed ID: 9109465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.